Original article
A three-gene resistome signature as a prognostic tool in hepatocellular carcinoma
Anabel Sanchez-Martina, Rocio I.R. Maciasa,f, Luis Muñoz-Bellvísb,c, Luis M. Gonzalezb, Alejandro Fornerd,e,f, Maria Reigd,e,f, Jose J.G. Marina,f,‡,
, Oscar Briza,f,‡,**
Corresponding author
jjgmarin@usal.es
Corresponding author. Jose J.G. Marin, Department of Physiology and Pharmacology, University of Salamanca, Campus Miguel de Unamuno, E.D., Lab-231, 37007, Salamanca, Spain.
Corresponding author. Jose J.G. Marin, Department of Physiology and Pharmacology, University of Salamanca, Campus Miguel de Unamuno, E.D., Lab-231, 37007, Salamanca, Spain.
Corresponding author
obriz@usal.es
Corresponding authors. Oscar Briz, Department of Physiology and Pharmacology, University of Salamanca, Campus Miguel de Unamuno, E.D., Lab-S05, 37007, Salamanca, Spain.
Corresponding authors. Oscar Briz, Department of Physiology and Pharmacology, University of Salamanca, Campus Miguel de Unamuno, E.D., Lab-S05, 37007, Salamanca, Spain.
a Experimental Hepatology and Drug Targeting (HEVEPHARM), Institute for Biomedical Research of Salamanca (IBSAL), University of Salamanca, Salamanca, Spain
b Service of General and Gastrointestinal Surgery, University Hospital of Salamanca, IBSAL, Salamanca, Spain
c Centro de Investigación Biomédica en Red del Cáncer (CIBERONC), Carlos III National Institute of Health, Madrid, Spain
d Liver Oncology Unit, Liver Unit, ICMDM, Hospital Clinic of Barcelona. University of Barcelona, Barcelona, Spain
e BCLC group, Fundació Recerca Clínic de Barcelona-Institut d'Investigació Biomèdica August Pi i Sunyer (FRCB-IDIBAPS), Barcelona, Spain
f Centro de Investigación Biomédica en Red de Enfermedades Hepáticas y Digestivas (CIBERehd), Carlos III National Institute of Health, Madrid, Spain
